ACRO Biomedical Co., Ltd. (TPEX:6748)
Taiwan · Delayed Price · Currency is TWD 66.60
-0.40 (-0.60%)
Apr 17, 2026, 1:57 PM CST
ACRO Biomedical Revenue
ACRO Biomedical had revenue of 13.32M TWD in the half year ending June 30, 2025, a decrease of -15.74%. This brings the company's revenue in the last twelve months to 36.50M, down -35.18% year-over-year. In the year 2024, ACRO Biomedical had annual revenue of 44.23M, down -13.38%.
Revenue (ttm)
36.50M
Revenue Growth
-35.18%
P/S Ratio
112.03
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.23M | -6.83M | -13.38% |
| Dec 31, 2023 | 51.06M | 23.43M | 84.79% |
| Dec 31, 2022 | 27.63M | 5.81M | 26.59% |
| Dec 31, 2021 | 21.83M | 3.80M | 21.04% |
| Dec 31, 2020 | 18.03M | 10.71M | 146.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medigen Biotechnology | 1.58B |
| Genovate Biotechnology | 492.41M |
| Sagittarius Life Science | 346.08M |
| BioGend Therapeutics | 222.34M |
| Pharmosa Biopharm | 67.27M |
| OBI Pharma | 58.58M |
| Shine-On BioMedical | 30.00M |
| Formosa Pharmaceuticals | 9.50M |